- $621.36m
- $603.55m
- $116.59m
Gyre Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a share - Earnings Preview
Brief: Gyre Therapeutics Reports Second Quarter 2026
Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumes
Brief: Gyre Therapeutics Announces NMPA Acceptance Of New Drug Application For F351 (Hydronidone)
Gyre Therapeutics Q1 revenue rises 2% but misses analyst estimates
Brief: Gyre Therapeutics Completes Acquisition Of Cullgen To Create U.S.- And China-Based Fully Integrated Biopharmaceutical Company
Brief: Gyre Therapeutics Announces China’S Nmpa Grants Priority Review To The NDA For Hydronidone (F351) For Chb-Induced Liver Fibrosis Treatment
U.S. STOCKS ON THE MOVE -Gyre Therapeutics, Nutrien Ltd, Rapid Micro Biosystems
U.S. STOCKS ON THE MOVE -Natera, Pacira BioSciences, Kezar Life Sciences
U.S. STOCKS ON THE MOVE-SciSparc, Natera, US energy companies
U.S. STOCKS ON THE MOVE-Bumble, Dick's Sporting Goods
Gyre Therapeutics falls on downbeat annual revenue outlook
Brief: Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Gyre Therapeutics Q4 revenue beats estimates on new product launch
U.S. STOCKS ON THE MOVE-Gitlab, ADT Inc, California Resources
U.S. STOCKS ON THE MOVE-Palantir Technologies, Cheniere Energy, Venture Global
Gyre Therapeutics falls after $300 million deal to buy Cullgen
Brief: Gyre Therapeutics Enters Into Agreement To Acquire Cullgen To Gain Targeted Protein Degradation Platform And Pipeline